UP FRONT MATTERS: Special ArticleANCA Disease Where Is This Field Heading?Falk, Ronald J.*; Jennette, J. Charles† Author Information *University of North Carolina Kidney Center and †Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina Correspondence: Dr. Ronald J. Falk, UNC Kidney Center, 7024 Burnett Womack/CB# 7155, University of North Carolina, Chapel Hill, NC 27599-7155. Phone: 919-966-2561; Fax: 919-966-4251; E-mail: [email protected]; URL: http://www.unckidneycenter.org Journal of the American Society of Nephrology 21(5):p 745-752, May 2010. | DOI: 10.1681/ASN.2009121238 Buy Metrics Abstract ANCA disease remains a subject of great experimental and clinical interest. The subcategories of names and descriptions for this collection of vasculitides and necrotizing glomerulonephritides is still a subject of some debate. The various forms of ANCA disease share some characteristics, and similar therapies are often recommended for overlapping categories of disease. The immunopathogenic effects of myeloperoxidase and proteinase 3 antibodies are well established, and good mechanisms for initiation of disease are starting to emerge, particularly the role of autoantigen complementarity. Here we examine these various topics and discuss an approach to treatment. Copyright © 2010 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.